AR054347A1 - Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion - Google Patents

Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Info

Publication number
AR054347A1
AR054347A1 ARP060101594A ARP060101594A AR054347A1 AR 054347 A1 AR054347 A1 AR 054347A1 AR P060101594 A ARP060101594 A AR P060101594A AR P060101594 A ARP060101594 A AR P060101594A AR 054347 A1 AR054347 A1 AR 054347A1
Authority
AR
Argentina
Prior art keywords
depression
treatment
prevention
therapeutic combinations
combinations
Prior art date
Application number
ARP060101594A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36809594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054347A1 publication Critical patent/AR054347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan combinaciones terapéuticas utiles en el tratamiento o prevencion de la depresion u otros trastornos del temperamento, composiciones farmacéuticas que contienen dichas combinaciones, y su uso en el tratamiento o profilaxis de la depresion u otros trastornos del temperamento. Tales compuestos son de formula (1), o una sal farmacéuticamente aceptable de los mismos, donde cada uno de R1, R2, R3, n, y, y Ar son como de definio y describio en la presente.
ARP060101594A 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion AR054347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67404805P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR054347A1 true AR054347A1 (es) 2007-06-20

Family

ID=36809594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101594A AR054347A1 (es) 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Country Status (13)

Country Link
US (2) US7396857B2 (es)
EP (1) EP1871355A1 (es)
JP (1) JP2008536946A (es)
CN (1) CN101198322A (es)
AR (1) AR054347A1 (es)
AU (1) AU2006239918A1 (es)
BR (1) BRPI0610044A2 (es)
CA (1) CA2604915A1 (es)
GT (1) GT200600163A (es)
MX (1) MX2007012882A (es)
PE (1) PE20061327A1 (es)
TW (1) TW200722081A (es)
WO (1) WO2006116149A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
US7470799B2 (en) * 2005-04-22 2008-12-30 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2605580A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
JP2008538578A (ja) * 2005-04-22 2008-10-30 ワイス 疼痛の治療
CA2604759A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
TW200716106A (en) * 2005-04-24 2007-05-01 Wyeth Corp Methods for modulating bladder function
CL2007000775A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
CN102250048B (zh) * 2011-06-03 2013-06-05 浙江工业大学 2-苯硒基甲基-2,3-二氢苯并呋喃及其制备与应用
CN106716129B (zh) * 2014-09-26 2019-04-19 福满代谢组技术有限公司 对抑郁症治疗药物的选项进行预测的方法
CN113631157A (zh) * 2019-02-17 2021-11-09 诺拉威尔治疗公司 用于治疗抑郁症和其它病症的组合物和方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513239A (en) 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
US3826835A (en) 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
JPS59186969A (ja) 1983-04-08 1984-10-23 Yoshitomi Pharmaceut Ind Ltd ベンゾフラン−およびベンゾピランカルボキサミド誘導体
JPH06316563A (ja) 1993-05-06 1994-11-15 Yoshitomi Pharmaceut Ind Ltd アミド化合物
ES2304041T3 (es) 1993-06-28 2008-09-01 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
DE19909760B4 (de) 1998-04-17 2015-05-21 Merck Patent Gmbh Benzofuran-Derivate
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
KR100446235B1 (ko) 2001-05-07 2004-08-30 엘지전자 주식회사 다중 후보를 이용한 움직임 벡터 병합 탐색 방법
CA2461381A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US20030134835A1 (en) 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US7208502B2 (en) 2002-01-18 2007-04-24 Maniv Energy Capital Methods of treating conditions associated with an Edg-3 receptor
US20030092770A1 (en) 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
WO2004089410A1 (ja) 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. 神経因性疼痛の予防及び／または治療剤
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050261347A1 (en) 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
JPWO2005073210A1 (ja) 2004-01-28 2007-09-06 キッセイ薬品工業株式会社 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
DE102004030099A1 (de) 2004-06-22 2006-01-12 Grünenthal GmbH Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren
WO2006000902A1 (en) 2004-06-25 2006-01-05 Pfizer Products Inc. Dihydrobenzofuran compounds and uses thereof
GT200500296A (es) 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
BRPI0610509A2 (pt) 2005-04-22 2010-06-29 Wyeth Corp tratamento de dependência a drogas
CA2604759A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US7470799B2 (en) 2005-04-22 2008-12-30 Wyeth Dihydrobenzofuran derivatives and uses thereof
JP2008538578A (ja) 2005-04-22 2008-10-30 ワイス 疼痛の治療
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
WO2006116151A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
AR055054A1 (es) 2005-04-22 2007-08-01 Wyeth Corp Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
CA2605587A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
TW200716106A (en) 2005-04-24 2007-05-01 Wyeth Corp Methods for modulating bladder function
CL2007000775A1 (es) 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.

Also Published As

Publication number Publication date
BRPI0610044A2 (pt) 2010-05-25
JP2008536946A (ja) 2008-09-11
GT200600163A (es) 2007-03-14
US7396857B2 (en) 2008-07-08
PE20061327A1 (es) 2007-01-02
CN101198322A (zh) 2008-06-11
AU2006239918A1 (en) 2006-11-02
TW200722081A (en) 2007-06-16
US20080269321A1 (en) 2008-10-30
CA2604915A1 (en) 2006-11-02
WO2006116149A1 (en) 2006-11-02
EP1871355A1 (en) 2008-01-02
US20060258715A1 (en) 2006-11-16
MX2007012882A (es) 2007-12-10

Similar Documents

Publication Publication Date Title
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
GT200600518A (es) Derivados de pirimidina
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP055867A (es) Derivados de pirrolopirimidina
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
UY30759A1 (es) Compuestos quimicos
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
UY31141A1 (es) Compuestos de piperidina y sus usos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal